China CAR T-Cell Therapy for Multiple Myeloma Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 CAR T-Cell Therapy for Multiple Myeloma Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China CAR T-Cell Therapy for Multiple Myeloma Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 China CAR T-Cell Therapy for Multiple Myeloma Overall Market Size
2.1 China CAR T-Cell Therapy for Multiple Myeloma Market Size: 2021 VS 2027
2.2 China CAR T-Cell Therapy for Multiple Myeloma Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CAR T-Cell Therapy for Multiple Myeloma Players in China Market
3.2 Top China CAR T-Cell Therapy for Multiple Myeloma Companies Ranked by Revenue
3.3 China CAR T-Cell Therapy for Multiple Myeloma Revenue by Companies
3.4 Top 3 and Top 5 CAR T-Cell Therapy for Multiple Myeloma Companies in China Market, by Revenue in 2020
3.5 Companies CAR T-Cell Therapy for Multiple Myeloma Product Type
3.6 Tier 1, Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Players in China Market
3.6.1 List of Tier 1 CAR T-Cell Therapy for Multiple Myeloma Companies in China
3.6.2 List of Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Companies in China
4 Sights by Type
4.1 Overview
4.1.1 By Type - China CAR T-Cell Therapy for Multiple Myeloma Market Size Markets, 2021 & 2027
4.1.2 Monotherapy
4.1.3 Combination Therapy
4.2 By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
4.2.1 By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue, 2016-2021
4.2.2 By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue, 2022-2027
4.2.3 By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - China CAR T-Cell Therapy for Multiple Myeloma Market Size, 2021 & 2027
5.1.2 Multiple Myeloma
5.1.3 Refractory or Relapsed Multiple Myeloma
5.2 By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
5.2.1 By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue, 2016-2021
5.2.2 By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue, 2022-2027
5.2.3 By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2016-2027
6 CAR T-Cell Therapy for Multiple Myeloma Companies Profiles
6.1 Juno Therapeutics
6.1.1 Juno Therapeutics Company Details
6.1.2 Juno Therapeutics Business Overview
6.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Introduction
6.1.4 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021)
6.1.5 Juno Therapeutics Recent Developments
6.2 Kite Pharma
6.2.1 Kite Pharma Company Details
6.2.2 Kite Pharma Business Overview
6.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Introduction
6.2.4 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021)
6.2.5 Kite Pharma Recent Developments
6.3 Novartis
6.3.1 Novartis Company Details
6.3.2 Novartis Business Overview
6.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Introduction
6.3.4 Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021)
6.3.5 Novartis Recent Developments
6.4 Collectis
6.4.1 Collectis Company Details
6.4.2 Collectis Business Overview
6.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Introduction
6.4.4 Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021)
6.4.5 Collectis Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of TablesTable 1. CAR T-Cell Therapy for Multiple Myeloma Market Opportunities & Trends in China Market
Table 2. CAR T-Cell Therapy for Multiple Myeloma Market Drivers in China Market
Table 3. CAR T-Cell Therapy for Multiple Myeloma Market Restraints in China Market
Table 4. Key Players of CAR T-Cell Therapy for Multiple Myeloma in China Market
Table 5. Top CAR T-Cell Therapy for Multiple Myeloma Players in China Market, Ranking by Revenue (2019)
Table 6. China CAR T-Cell Therapy for Multiple Myeloma Revenue by Companies, (US$, Mn), 2016-2021
Table 7. China CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Companies, 2016-2021
Table 8. Companies CAR T-Cell Therapy for Multiple Myeloma Product Type
Table 9. List of Tier 1 CAR T-Cell Therapy for Multiple Myeloma Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2016-2021
Table 13. By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2022-2027
Table 14. By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2016-2021
Table 16. By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2022-2027
Table 17. Juno Therapeutics Company Details
Table 18. Juno Therapeutics Business Overview
Table 19. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Product
Table 20. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021) & (US$ Million)
Table 21. Juno Therapeutics Recent Developments
Table 22. Kite Pharma Company Details
Table 23. Kite Pharma Business Overview
Table 24. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Product
Table 25. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021) & (US$ Million)
Table 26. Kite Pharma Recent Developments
Table 27. Novartis Company Details
Table 28. Novartis Business Overview
Table 29. Novartis CAR T-Cell Therapy for Multiple Myeloma Product
Table 30. Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021) & (US$ Million)
Table 31. Novartis Recent Developments
Table 32. Collectis Company Details
Table 33. Collectis Business Overview
Table 34. Collectis CAR T-Cell Therapy for Multiple Myeloma Product
Table 35. Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue in China Market (2016-2021) & (US$ Million)
Table 36. Collectis Recent Developments
List of FiguresFigure 1. CAR T-Cell Therapy for Multiple Myeloma Segment by Type
Figure 2. CAR T-Cell Therapy for Multiple Myeloma Segment by Application
Figure 3. China CAR T-Cell Therapy for Multiple Myeloma Market Overview: 2020
Figure 4. China CAR T-Cell Therapy for Multiple Myeloma Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. China CAR T-Cell Therapy for Multiple Myeloma Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2020
Figure 7. By Type - China CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2016-2027
Figure 8. By Application - China CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2016-2027
Figure 9. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
